171 |
Drug Coated Balloons for Femoropopliteal Disease - Insights from Randomized Trials and Global Registries |
John Robert Laird, Jr. |
Apr. 21. 16 |
170 |
Best Approach Using DCB, Atherectomy, DES or BVS in BTK |
Lawrence A. Garcia |
Apr. 21. 16 |
169 |
Novel Therapy in CLI as Stem Cells, Growth Factors, Are They Clinically Beneficial or Horizon Therapy? |
Krishna Rocha-Singh |
Apr. 21. 16 |
168 |
What Is the Best Angiographic Endpoint for Revascularization?(Angiosome or "Straight-Line" Flow) |
Osamu Iida |
Apr. 21. 16 |
167 |
Current and Upcoming Evidence-Based Approach in CLI: Endovascular vs. Surgery (OLIVE 3-Year and BEST-CLI Trial) |
Mark W. Burket |
Apr. 21. 16 |
166 |
CLI: Best Medical Therapy - Statin, Antiplatelet, Smoking and Guidelines-Based Management |
John Robert Laird, Jr. |
Apr. 21. 16 |
165 |
DCB or DES in SFA treatment: A Difficult Choice? |
Herman Schroë |
Apr. 21. 16 |
164 |
Not Alone, Combination Might Be Better, Which One Could Be Better?: Atherectomy with DCB |
Ravish Sachar |
Apr. 21. 16 |
163 |
Novel Stent Technology Can Shed Light: SUPERA or BVS |
Richard R. Heuser |
Apr. 21. 16 |
162 |
Drug-Eluting Stents in the SFA(Zilver PTX or ELUVIA): Why Not Now? What Needed for the Future? |
Mark W. Burket |
Apr. 21. 16 |